X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES WYETH LTD ALKEM LABORATORIES/
WYETH LTD
 
P/E (TTM) x - 27.7 - View Chart
P/BV x 7.1 5.3 132.4% View Chart
Dividend Yield % 0.6 1.3 48.1%  

Financials

 ALKEM LABORATORIES   WYETH LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
WYETH LTD
Mar-13
ALKEM LABORATORIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,5891,044 152.1%   
Low Rs1,232818 150.6%   
Sales per share (Unadj.) Rs417.5298.6 139.8%  
Earnings per share (Unadj.) Rs56.357.2 98.3%  
Cash flow per share (Unadj.) Rs64.758.4 110.8%  
Dividends per share (Unadj.) Rs12.7017.00 74.7%  
Dividend yield (eoy) %0.91.8 49.3%  
Book value per share (Unadj.) Rs292.9249.5 117.4%  
Shares outstanding (eoy) m119.5722.72 526.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.1 108.3%   
Avg P/E ratio x25.116.3 154.0%  
P/CF ratio (eoy) x21.815.9 136.7%  
Price / Book Value ratio x4.83.7 129.0%  
Dividend payout %22.629.7 76.0%   
Avg Mkt Cap Rs m168,65321,157 797.2%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m9,171400 2,292.8%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m49,9156,783 735.8%  
Other income Rs m1,645353 466.6%   
Total revenues Rs m51,5617,136 722.5%   
Gross profit Rs m8,4821,617 524.5%  
Depreciation Rs m1,00627 3,781.2%   
Interest Rs m6716 12,192.7%   
Profit before tax Rs m8,4511,938 436.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,606632 254.0%   
Profit after tax Rs m6,7311,301 517.6%  
Gross profit margin %17.023.8 71.3%  
Effective tax rate %19.032.6 58.2%   
Net profit margin %13.519.2 70.3%  
BALANCE SHEET DATA
Current assets Rs m27,0626,984 387.5%   
Current liabilities Rs m15,3242,056 745.3%   
Net working cap to sales %23.572.6 32.4%  
Current ratio x1.83.4 52.0%  
Inventory Days Days6799 67.0%  
Debtors Days Days4124 172.4%  
Net fixed assets Rs m12,610244 5,161.5%   
Share capital Rs m239227 105.2%   
"Free" reserves Rs m34,4905,441 633.9%   
Net worth Rs m35,0275,668 618.0%   
Long term debt Rs m1,21225 4,846.4%   
Total assets Rs m54,3877,901 688.4%  
Interest coverage x13.6353.3 3.8%   
Debt to equity ratio x00 784.2%  
Sales to assets ratio x0.90.9 106.9%   
Return on assets %13.616.5 82.3%  
Return on equity %19.222.9 83.8%  
Return on capital %24.934.0 73.0%  
Exports to sales %12.90.2 5,932.8%   
Imports to sales %3.136.3 8.5%   
Exports (fob) Rs m6,46115 43,656.1%   
Imports (cif) Rs m1,5402,465 62.5%   
Fx inflow Rs m6,56315 43,179.6%   
Fx outflow Rs m3,0122,677 112.5%   
Net fx Rs m3,552-2,662 -133.4%   
CASH FLOW
From Operations Rs m7,259923 786.2%  
From Investments Rs m1,864317 588.3%  
From Financial Activity Rs m-9,273-481 1,927.8%  
Net Cashflow Rs m-150759 -19.8%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 33.1 11.3 292.9%  
FIIs % 0.0 7.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 30.4 -  
Shareholders   68,381 21,978 311.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  MERCK LTD  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 26, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS